financetom
Business
financetom
/
Business
/
Form 8.3 - Dalata Hotel Group plc
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Dalata Hotel Group plc
Oct 31, 2025 5:40 AM

LONDON--(BUSINESS WIRE)--

 

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

(a) Full name of discloser

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

Dalata Hotel Group plc ( DLTTF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

 

(e) Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

30-10-2025

(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security
(Note 3)

€0.01 ordinary shares

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

0

0

0

0

(2) Cash-settled derivatives

6,742,921

3.18

0

0

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

0

0

0

0

Total

6,742,921

3.18

0

0

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant
security

Purchase/sale

Number of
securities

Price per unit
(Note 5)

 

 

 

 

 

Ap29

(b) Cash-settled derivative transactions

Class of
relevant
security

Product
description
e.g. CFD

Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

Number of
reference
securities
(Note 6)

Price
per unit
(Note 5)

€0.01 ordinary shares

Equity Swap

Increasing a long position

877

6.43

€0.01 ordinary shares

Equity Swap

Decreasing a long position

5,356

6.43

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of
relevant
security

Product
description e.g. call
option

Writing, purchasing, selling, varying
etc.

Number
of
securities
to which
option
relates
(Note 6)

Exercise
price per
unit

Type
e.g.
American,
European
etc.

Expiry
date

Option
money
paid/
received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of
relevant
security

Product
description
e.g. call
option

Exercising/
exercised
against

Number of
securities

Exercise
price per
unit
(Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security

Nature of dealing
e.g. subscription,
conversion, exercise

Details

Price per unit (if
applicable)
(Note 5)

 

 

 

 

 

Ap30

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

(c) Attachments

Is a Supplemental Form 8 attached?

NO

Class of relevant security
(Note 3)

€0.01 ordinary shares

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

0

0

0

0

(2) Cash-settled derivatives

6,742,921

3.18

0

0

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

0

0

0

0

Total

6,742,921

3.18

0

0

0

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tyra Biosciences Shares Retreat After Gains Following Positive Clinical Trial Results for TYRA-300
Tyra Biosciences Shares Retreat After Gains Following Positive Clinical Trial Results for TYRA-300
Nov 3, 2024
12:39 PM EDT, 10/25/2024 (MT Newswires) -- Tyra Biosciences ( TYRA ) shares were down more than 21% in recent Friday trading, reversing earlier gains spurred by the company's disclosure of positive clinical proof-of-concept data for TYRA-300. The company said Thursday that preliminary data from its ongoing SURF301 phase 1/2 study showed TYRA-300, an investigational oral fibroblast growth factor receptor-selective...
Thiel's Palantir dumped by Norwegian investor over work for Israel
Thiel's Palantir dumped by Norwegian investor over work for Israel
Nov 3, 2024
LONDON/OSLO (Reuters) - One of the Nordic region's largest investors has sold its holdings in Palantir Technologies ( PLTR ) because of concerns that the U.S. data firm's work for Israel might put the asset manager at risk of violating international humanitarian law and human rights.  Storebrand Asset Management disclosed this week that it had excluded Palantir Technologies Inc. (...
E. coli infections tied to McDonald's burgers rise to 75, US FDA says
E. coli infections tied to McDonald's burgers rise to 75, US FDA says
Nov 3, 2024
Oct 25 (Reuters) - The number of people infected by the E. coli outbreak tied to McDonald's Quarter Pounder hamburgers increased to 75 from 49, the U.S. Food and Drug Administration said on Friday. Of the 61, on whom information was available, the health regulator said 22 persons have been hospitalized. Two of them have developed hemolytic uremic syndrome, a...
Builders FirstSource Likely to Expand Earnings Faster Than Expected, UBS Says
Builders FirstSource Likely to Expand Earnings Faster Than Expected, UBS Says
Nov 3, 2024
12:46 PM EDT, 10/25/2024 (MT Newswires) -- Builders FirstSource ( BLDR ) is likely to expand its earnings faster than expected, driving potential upside to its share price, UBS Securities said Friday in a note initiating coverage of the company. The firm said it was forecasting a roughly 13% adjusted earnings per share compound annual growth rate through 2026, well...
Copyright 2023-2026 - www.financetom.com All Rights Reserved